Drug Details
| General Information of the Drug (ID: DR1563) | ||||
|---|---|---|---|---|
| Name |
Tamoxifen
|
|||
| Synonyms |
tamoxifen; 10540-29-1; trans-Tamoxifen; Crisafeno; Soltamox; Tamoxifene; Diemon; Tamoxifenum; Tamoxifeno; Tamizam; Istubol; Tamoxen; Citofen; Oncomox; Valodex; Retaxim; Tamoxifene [INN-French]; Tamoxifenum [INN-Latin]; Tamoxifeno [INN-Spanish]; Tamoxifen (Z); Tamoxifen and its salts; Tamoxifen [INN:BAN]; ICI-46474; ICI 47699; TRANS FORM OF TAMOXIFEN; CCRIS 3275; UNII-094ZI81Y45; HSDB 6782; CHEMBL83; EINECS 234-118-0; 1-p-beta-Dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene; Citofen; Nourytam; Novaldex; Tamone; Tamoxifeno; Tamoxifenum; Tomaxithen; Gen-Tamoxifen; Istubal (TN); Nolvadex (TN); Nolvadex-D; Novo-Tamoxifen; Pms-Tamoxifen; Tamoplex (TN); Tamoxifen (INN); Tamoxifen (TN); Trans-Tamoxifen; Valodex (TN); TAMOXIFEN (TAMOXIFEN CITRATE (54965-24-1)); Trans-2-[4-(1,2-Diphenyl-1-butenyl)phenoxy]-N,N-dimethylethylamine; (Z)-1-(p-Dimethylaminoethoxyphenyl)-1,2-diphenyl-1-butene; (Z)-2-(4-(1,2-Diphenyl-1-butenyl)phenoxy)-N,N-dimethylethanamine; (Z)-2-(4-(1,2-diphenylbut-1-enyl)phenoxy)-N,N-dimethylethanamine; (Z)-2-(para-(1,2-Diphenyl-1-butenyl)phenoxy)-N,N-dimethylamine (IUPAC); (Z)-2-[4-(1,2)-DIPHENYL-1-BUTENYL)-PHENOXY]-N,N-DIMETHYLETHANAMINE; (Z)-2-[p-(1,2-Diphenyl-1-butenyl)phenoxy]-N,N-dimethylethylamine; 1-p-beta-Dimethylamino-ethoxyphenyl-trans-1,2-diphenylbut-1-ene; 1-para-beta-Dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene; 2-[4-[(Z)-1,2-diphenylbut-1-enyl]phenoxy]-N,N-dimethylethanamine; 2-{4-[(1Z)-1,2-diphenylbut-1-en-1-yl]phenoxy}-N,N-dimethylethanamine; Tamoxifen (Hormonal therapy); [3H]tamoxifen
Click to Show/Hide
|
|||
| Molecular Type |
Small molecule
|
|||
| Disease | Breast cancer [ICD-11: 2C60] | Approved | [1] | |
| Structure |
|
Click to Download Mol2D MOL |
||
| ADMET Property |
Absorption Cmax
The maximum plasma concentration (Cmax) of drug is 40 mcg/L
Absorption Tmax
The time to maximum plasma concentration (Tmax) is 5 h
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability
Clearance
The clearance of drug is 189 mL/min in postmenopausal women
Elimination
Animal studies have shown 75% of radiolabelled tamoxifen recovered in the feces, with negligible collection from urine
Half-life
The concentration or amount of drug in body reduced by one-half in 5 - 7 days
Metabolism
The drug is metabolized via the hydroxylated to -hydroxytamoxifen
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 1.18283 micromolar/kg/day
Vd
The volume of distribution (Vd) of drug is 50-60 L/kg
Water Solubility
The ability of drug to dissolve in water is measured as 0.5 mg/mL
Click to Show/Hide
|
|||
| Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product | ||||
| Formula |
C26H29NO
|
|||
| PubChem CID | ||||
| Canonical SMILES |
CCC(=C(C1=CC=CC=C1)C2=CC=C(C=C2)OCCN(C)C)C3=CC=CC=C3
|
|||
| InChI |
1S/C26H29NO/c1-4-25(21-11-7-5-8-12-21)26(22-13-9-6-10-14-22)23-15-17-24(18-16-23)28-20-19-27(2)3/h5-18H,4,19-20H2,1-3H3/b26-25-
|
|||
| InChIKey |
NKANXQFJJICGDU-QPLCGJKRSA-N
|
|||
| CAS Number |
CAS 10540-29-1
|
|||
| ChEBI ID | ||||
| GDSC | ||||
| TTD Drug ID | ||||
| DrugBank ID | ||||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. A List of Natural Product(s) Able to Enhance the Efficacy of This Drug | ||||||
| Carnosic acid | Salvia rosmarinus | Click to Show/Hide the Molecular Data of This NP | ||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [2] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Up-regulation | Expression | BAD | Molecule Info |
Pathway MAP
|
|
| Up-regulation | Expression | BAK | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | BAX | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | BCL-2 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | BCL-xL | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Cleavage | CASP3 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Cleavage | CASP8 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Cleavage | PARP1 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | TNFRSF10C | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | TNFRSF10D | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | TNFSF10 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | TP53 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | TP73 | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | MCF-7 | CVCL_0031 | Invasive breast carcinoma | Homo sapiens | ||
| T-47D | CVCL_0553 | Invasive breast carcinoma | Homo sapiens | |||
| In-vivo Model | 5*105 MCF-7 cells were subcutaneously injected into the dorsal flanks of athymic nude mice. | |||||
| Experimental
Result(s) |
Carnosic acid cooperates with tamoxifen to induce apoptosis associated with Caspase-3 activation in breast cancer cells in vitro and in vivo. | |||||
| Curcumin | Hellenia speciosa | Click to Show/Hide the Molecular Data of This NP | ||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [3] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Down-regulation | Expression | BCL-2 | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Expression | BCL-xL | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | CCND1 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | CDKN1A | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | EZH2 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | FAK | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | IKKA | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | IKKB | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Phosphorylation | mTOR | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | MYC | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Phosphorylation | RELA | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Phosphorylation | S6K1 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Phosphorylation | SRC | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | MCF-7 | CVCL_0031 | Invasive breast carcinoma | Homo sapiens | ||
| Experimental
Result(s) |
The combination of curcumin and tamoxifen resulted in a synergistic survival inhibition in MCF-7/LCC2 and MCF-7/LCC9 cells. | |||||
| Cyclopamine | Veratrum californicum | Click to Show/Hide the Molecular Data of This NP | ||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [4] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Up-regulation | Expression | Gli1 | Molecule Info |
Pathway MAP
|
|
| In-vitro Model | MCF-7 | CVCL_0031 | Invasive breast carcinoma | Homo sapiens | ||
| Experimental
Result(s) |
Combination of cyclopamine and tamoxifen promotes survival and migration of mcf-7 breast cancer cells--interaction of hedgehog-gli and estrogen receptor signaling pathways. | |||||
| Epigallocatechin gallate | Hamamelis virginiana | Click to Show/Hide the Molecular Data of This NP | ||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [5] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Down-regulation | Expression | CYP1B1 | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Expression | EGFR | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | mTOR | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | MDA-MB-231 | CVCL_0062 | Breast adenocarcinoma | Homo sapiens | ||
| MCF-7 | CVCL_0031 | Invasive breast carcinoma | Homo sapiens | |||
| In-vivo Model | Female CD1 athymic nude mice were inoculated into the right flank with MDA-MB-231 cells (2*106/50L matrigel), which were left to form palpable tumours. | |||||
| Experimental
Result(s) |
Tamoxifen at realistic doses (75 mug kg(-1)) can suppress the growth of ER-negative breast cancer when combined with EGCG. The dominant mechanism for tumour suppression is the concomitant decrease in tumour protein expressions of mTOR and the EGFR. | |||||
| Genistein | Glycine max | Click to Show/Hide the Molecular Data of This NP | ||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [6] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Down-regulation | Expression | EGFR | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Expression | ESR | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | HER2 | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | BT-474 | CVCL_0179 | Invasive breast carcinoma | Homo sapiens | ||
| Experimental
Result(s) |
Genistein sensitizes inhibitory effect of tamoxifen on the growth of estrogen receptor-positive and HER2-overexpressing human breast cancer cells. | |||||
| Methylselenocysteine | Astragalus bisulcatus | Click to Show/Hide the Molecular Data of This NP | ||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [7] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Down-regulation | Expression | CCND1 | Molecule Info |
Pathway MAP
|
|
| In-vitro Model | MCF-7 | CVCL_0031 | Invasive breast carcinoma | Homo sapiens | ||
| In-vivo Model | About 5*106 cells suspension in 50 uL sterile PBS were mixed with 100 uL Matrigel and administered within both sides of the inguinal mammary fat pad of NU/NU immune-compromised female ovariectomized mice. | |||||
| Experimental
Result(s) |
These findings demonstrate synergistic growth inhibition of ERalpha positive breast cancer xenografts by combination of tamoxifen with organic selenium compounds. | |||||
| Oxyprogesterone caproate | Homo sapiens | Click to Show/Hide the Molecular Data of This NP | ||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [8] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Experimental
Result(s) |
Oxyprogesterone caproate (OPC) administered preoperatively and after surgical and combined therapy from 6 up to 36 months increased the corrected survival rates as compared with that in patients who did not receive hormone treatment. | |||||
| Pancratistatin | Pancratium littorale | Click to Show/Hide the Molecular Data of This NP | ||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [9] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Biological
Regulation |
Increase | ROS generation | ||||
| In-vitro Model | MCF-7 | CVCL_0031 | Invasive breast carcinoma | Homo sapiens | ||
| Experimental
Result(s) |
In combination with the anti-estrogen Tamoxifen, PST had a synergic effect. | |||||
| Pterostilbene | Vitis vinifera | Click to Show/Hide the Molecular Data of This NP | ||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [10] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| In-vitro Model | MCF-7 | CVCL_0031 | Invasive breast carcinoma | Homo sapiens | ||
| ZR-75-1 | CVCL_0588 | Invasive breast carcinoma | Homo sapiens | |||
| Experimental
Result(s) |
Pterostilbene shows an additive inhibitory effect on breast cancer cells when combined with tamoxifen, most likely from augmented cancer cell apoptosis. | |||||
| Thymoquinone | Nigella sativa | Click to Show/Hide the Molecular Data of This NP | ||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [11] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| In-vitro Model | MCF-7 | CVCL_0031 | Invasive breast carcinoma | Homo sapiens | ||
| MDA-MB-231 | CVCL_0062 | Breast adenocarcinoma | Homo sapiens | |||
| Experimental
Result(s) |
The synergistic effect of TQ and TAM on human breast cancer cell lines showed cell viability reduction as well as apoptosis induction, independent to estrogen. | |||||
| Vinblastine | Catharanthus roseus | Click to Show/Hide the Molecular Data of This NP | ||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [12] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| In-vitro Model | NCI-H1299 | CVCL_0060 | Lung large cell carcinoma | Homo sapiens | ||
| MDA-MB-231 | CVCL_0062 | Breast adenocarcinoma | Homo sapiens | |||
| Experimental
Result(s) |
Combination therapy of breast and lung cancer cell lines using docetaxel or vinblastine with tamoxifen synergistically increases the anti-proliferative affect of single agents. | |||||
| β. A List of Natural Product(s) Able to Decrease the Adverse Effect of This Drug | ||||||
| Vincamine | Vinca minor | Click to Show/Hide the Molecular Data of This NP | ||||
| Decreasing Adverse Drug Reaction | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [13] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Down-regulation | Expression | CASP3 | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Phosphorylation | ERK1 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Phosphorylation | JNK1 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | p105 | Molecule Info |
Pathway MAP
|
||
| In-vivo Model | Adult female Wistar albino rats were used in this study. | |||||
| Experimental
Result(s) |
Zafirlukast and vincamine may be regarded as potential therapeutic strategies with antioxidant and anti-inflammatory activities against tamoxifen-induced oxidative damage in rat liver. | |||||
| γ. A List of Natural Product(s) Able to Reverse the Resistance of This Drug | ||||||
| Luteolin | Abrus precatorius | Click to Show/Hide the Molecular Data of This NP | ||||
| Reversing Drug Resistance | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [14] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Down-regulation | Expression | CCNE2 | Molecule Info |
Pathway MAP
|
|
| In-vitro Model | MCF-7 | CVCL_0031 | Invasive breast carcinoma | Homo sapiens | ||
| BT-483 | CVCL_2319 | Invasive breast carcinoma | Homo sapiens | |||
| BT-474 | CVCL_0179 | Invasive breast carcinoma | Homo sapiens | |||
| MDA-MB-231 | CVCL_0062 | Breast adenocarcinoma | Homo sapiens | |||
| AU565 | CVCL_1074 | Breast adenocarcinoma | Homo sapiens | |||
| MCF-10A | CVCL_0598 | Healthy | Homo sapiens | |||
| Experimental
Result(s) |
Luteolin sensitises drug-resistant human breast cancer cells to tamoxifen via the inhibition of cyclin E2 expression. | |||||
| Target and Pathway | ||||
|---|---|---|---|---|
| Target(s) | Estrogen receptor (ESR) | Molecule Info | [15] | |
| KEGG Pathway | Estrogen signaling pathway | Click to Show/Hide | ||
| 2 | Prolactin signaling pathway | |||
| 3 | Thyroid hormone signaling pathway | |||
| 4 | Endocrine and other factor-regulated calcium reabsorption | |||
| 5 | Proteoglycans in cancer | |||
| NetPath Pathway | FSH Signaling Pathway | Click to Show/Hide | ||
| 2 | EGFR1 Signaling Pathway | |||
| 3 | RANKL Signaling Pathway | |||
| Pathway Interaction Database | Regulation of nuclear SMAD2/3 signaling | Click to Show/Hide | ||
| 2 | Signaling events mediated by HDAC Class II | |||
| 3 | Plasma membrane estrogen receptor signaling | |||
| 4 | LKB1 signaling events | |||
| 5 | Regulation of Telomerase | |||
| 6 | ATF-2 transcription factor network | |||
| 7 | AP-1 transcription factor network | |||
| 8 | FOXM1 transcription factor network | |||
| 9 | Validated nuclear estrogen receptor alpha network | |||
| 10 | Signaling mediated by p38-alpha and p38-beta | |||
| 11 | FOXA1 transcription factor network | |||
| Reactome | Nuclear signaling by ERBB4 | Click to Show/Hide | ||
| 2 | Nuclear Receptor transcription pathway | |||
| WikiPathways | Estrogen signaling pathway | Click to Show/Hide | ||
| 2 | Nuclear Receptors Meta-Pathway | |||
| 3 | Estrogen Receptor Pathway | |||
| 4 | Signaling by ERBB4 | |||
| 5 | JAK/STAT | |||
| 6 | Integrated Pancreatic Cancer Pathway | |||
| 7 | Leptin signaling pathway | |||
| 8 | miR-targeted genes in muscle cell - TarBase | |||
| 9 | Integrated Breast Cancer Pathway | |||
| 10 | Nuclear Receptors | |||